Apricus shares slide 67% on new Vitaros CRL

19 February 2018

Apricus Biosciences (Nasdaq: APRI) saw its market value take a nosedive on Friday following news that the company had received a complete response letter (CRL) for the New Drug Application of Vitaros (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.

The USA-based urology and rheumatology specialist closed at $1.04 on Friday, a fall of 67% compared to the previous close.

In the CRL, the FDA indicates that it cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to chemistry, manufacturing and control (CMC) and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK